A new analysis questions the assumption that bets in medtech companies pay off more quickly and surely than biopharma investments. However, when medical device companies win, they win big. Now that the dust is settling, an analysis finds that relative to bio-pharmaceutical investments, medical device companies are more likely to have a binary outcome, require more time to exit, and are consuming an increasing proportion of capital in later rounds of financing.
Read the article (PDF)